Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). BioPharma Credit's share price for the quarter that ended in Dec. 2022 was $0.95. BioPharma Credit's Shares Outstanding (EOP) for the quarter that ended in Dec. 2022 was 1,319.2 Mil. Therefore, BioPharma Credit's market cap for the quarter that ended in Dec. 2022 was $1,253.2 Mil.
BioPharma Credit's quarterly market cap
declined
from Dec. 2021 ($1,329.9 Mil) to Jun. 2022 ($1,291.4 Mil) and
declined
from Jun. 2022 ($1,291.4 Mil) to Dec. 2022 ($1,253.2 Mil).
BioPharma Credit's annual market cap
declined
from Dec. 2021 ($1,329.9 Mil) to Dec. 2022 ($1,253.2 Mil) and
declined
from Dec. 2022 ($1,253.2 Mil) to Dec. 2023 ($1,094.3 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. BioPharma Credit's Enterprise Value for Today is $942.7 Mil.
BioPharma Credit Market Cap Historical Data
The historical data trend for BioPharma Credit's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of BioPharma Credit's Market Cap
For the Asset Management subindustry, BioPharma Credit's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioPharma Credit's Market Cap Distribution in the Asset Management Industry
For the Asset Management industry and Financial Services sector, BioPharma Credit's Market Cap distribution charts can be found below:
* The bar in red indicates where BioPharma Credit's Market Cap falls into.
BioPharma Credit Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
BioPharma Credit's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioPharma Credit (LSE:BPCR) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
BioPharma Credit Market Cap Related Terms
Thank you for viewing the detailed overview of BioPharma Credit's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
BioPharma Credit PLC is an investment company. The investment objective of the company is to generate long-term shareholder returns predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The only reporting segment of the company is the investment in debt assets secured by royalties or other cash flows derived from the sale of approved life sciences products. The company generates revenue in the form of interest income, income from subsidiaries, royalty revenue, make-whole and prepayment income, dividends, and paydown fees. The company earns a majority of its revenue from Investment income.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LSE:BPCR has been successfully added to your 